Manu Chakravarthy
Hoofd Techniek/Wetenschap/O&O bij Carmot Therapeutics, Inc.
Actieve functies van Manu Chakravarthy
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Hoofd Techniek/Wetenschap/O&O | 01-03-2021 | - |
Loopbaan van Manu Chakravarthy
Eerdere bekende functies van Manu Chakravarthy
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| AXCA HEALPAR | Hoofd Techniek/Wetenschap/O&O | 01-08-2017 | 05-03-2021 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01-08-2015 | 01-06-2017 |
Opleiding van Manu Chakravarthy
| Saint John's University | Undergraduate Degree |
| University of Texas Graduate School of Biomedical Sciences | Doctorate Degree |
| The University of Texas Medical School At Houston | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 7 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 2 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| AXCA HEALPAR | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Beurs
- Insiders
- Manu Chakravarthy
- Ervaring
